Azilsartan causes natriuresis due to its sympatholytic action in kidney disease.
Angiotensin II Type 1 Receptor Blockers
/ pharmacology
Angiotensin-Converting Enzyme 2
Animals
Benzimidazoles
/ pharmacology
Blood Pressure
/ drug effects
Creatinine
/ blood
Kidney
/ drug effects
Male
Natriuresis
/ drug effects
Oxadiazoles
/ pharmacology
Peptidyl-Dipeptidase A
/ metabolism
Rats
Rats, Inbred WKY
Renal Insufficiency, Chronic
/ physiopathology
Sodium
/ urine
Sympatholytics
/ pharmacology
Angiotensin receptor blocker
Chronic kidney disease
Natriuresis
Sympathetic nervous system
Journal
Hypertension research : official journal of the Japanese Society of Hypertension
ISSN: 1348-4214
Titre abrégé: Hypertens Res
Pays: England
ID NLM: 9307690
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
received:
01
11
2018
accepted:
20
04
2019
revised:
09
04
2019
pubmed:
30
5
2019
medline:
6
10
2020
entrez:
30
5
2019
Statut:
ppublish
Résumé
The sympathoinhibitory mechanism of azilsartan was investigated in an adenine-induced chronic renal failure model. Azilsartan exerted an antihypertensive effect, though BP elevation induced by adenine was marginal. The creatinine value was significantly lower in the azilsartan group (AZ) than in the vehicle group (VEH); furthermore, proteinuria was suppressed, and sodium excretion was augmented in the AZ group. The low frequency (LF) of systolic BP was suppressed (VEH: 4.07 ± 2.67 mmHg
Identifiants
pubmed: 31138899
doi: 10.1038/s41440-019-0271-1
pii: 10.1038/s41440-019-0271-1
doi:
Substances chimiques
Angiotensin II Type 1 Receptor Blockers
0
Benzimidazoles
0
Oxadiazoles
0
Sympatholytics
0
Sodium
9NEZ333N27
Creatinine
AYI8EX34EU
Peptidyl-Dipeptidase A
EC 3.4.15.1
Ace2 protein, rat
EC 3.4.17.23
Angiotensin-Converting Enzyme 2
EC 3.4.17.23
azilsartan
F9NUX55P23
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM